Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer
Status:
Withdrawn
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine the effectiveness of standard 3 weekly treatments
using docetaxel and prednisone with metformin in patients with castration-resistant
metastatic prostate cancer.
It is also being conducted to determine the levels of toxicity of metformin when added to
every 3 weekly docetaxel treatments in patients with endocrine resistent, metastatic prostate
cancer.